Cargando…
Development of novel agents for the treatment of early estrogen receptor positive breast cancer()
Estrogen receptor (ER+) breast cancer is the most frequently diagnosed breast cancer subtype. Currently, adjuvant treatment for early stage disease consists of endocrine therapy, with or without chemotherapy and bone-targeted therapy, delivered in a risk-adapted manner. Despite this multimodal appro...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9097798/ https://www.ncbi.nlm.nih.gov/pubmed/34903444 http://dx.doi.org/10.1016/j.breast.2021.11.007 |